Imexpharm Corporation (HOSE:IMP)

Vietnam flag Vietnam · Delayed Price · Currency is VND
52,000
+300 (0.58%)
At close: Jun 5, 2025
66.04%
Market Cap 7.96T
Revenue (ttm) 2.31T
Net Income (ttm) 309.16B
Shares Out 154.01M
EPS (ttm) 2,007.45
PE Ratio 25.75
Forward PE n/a
Dividend 500.00 (0.96%)
Ex-Dividend Date Jun 9, 2025
Volume 213,534
Average Volume 337,368
Open 51,700
Previous Close 51,700
Day's Range 51,700 - 52,100
52-Week Range 30,682 - 56,500
Beta 0.75
RSI 59.78
Earnings Date Jul 18, 2025

About Imexpharm

Imexpharm Corporation manufactures, processes, trades, imports, and exports pharmaceutical products in Vietnam and internationally. The company’s products include oral and injectable antibiotic, digestion, central nervous system, cardiovascular, diabetes, ophthalmology, musculoskeletal system, respiratory system, analgesic-anti-inflammatory- antipyretics, anti-histamines, anti-allergy, anti-parasitic, and external drugs, as well as vitamins and minerals, and supplement. It is also involved in the import and export of medical equipment and suppl... [Read more]

Industry Pharmaceutical Preparations
Founded 1977
Employees 1,452
Stock Exchange Ho Chi Minh Stock Exchange
Ticker Symbol IMP
Full Company Profile

Financial Performance

In 2024, Imexpharm's revenue was 2.21 trillion, an increase of 10.59% compared to the previous year's 1.99 trillion. Earnings were 297.54 billion, an increase of 16.85%.

Financial Statements

News

There is no news available yet.